Capecitabine

22 registered clinical trials studyying Capecitabine — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated H NCT06602167	Affiliated Hospital of Qinghai University	N/A
Not Yet Recruiting	First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable NCT06616259	Meng Qiu	Phase 3
Recruiting	NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC NCT06405490	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2
Unknown	Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC NCT06202014	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2
Completed	Topical Diclofenac for Hand-Foot Syndrome Prevention in Colorectal and Gastric Cancer on Capecitabine (DICLO-H NCT07177560	Gazi University	—
Recruiting	XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC NCT05970302	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2
Not Yet Recruiting	Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III C NCT05841134	The First Affiliated Hospital of Zhengzhou University	Phase 2
Unknown	A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patie NCT06169202	China Medical University, China	—
Unknown	Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Cap NCT06188000	Universitas Sriwijaya	N/A
Recruiting	UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases NCT05535413	Hunan Cancer Hospital	Phase 1 / Phase 2
Recruiting	Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcin NCT05290194	Fifth Affiliated Hospital, Sun Yat-Sen University	Phase 2
Completed	Pharmaceutical Care for Patients Using Capecitabine NCT07063706	Faculdade de Farmácia	N/A
Completed	The Therapeutic Effect of Different Doses of Capecitabine NCT06246461	Jingjiang People's Hospital	N/A
Recruiting	First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes NCT05022030	West China Hospital	Phase 2
Completed	Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. NCT04720131	Beijing Friendship Hospital	Phase 2
Unknown	The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer NCT03889626	Fudan University	Phase 3
Unknown	A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or NCT03500380	RemeGen Co., Ltd.	Phase 2 / Phase 3
Unknown	Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Pa NCT03258099	Cui Yimin	—
Completed	Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma NCT03079427	Asan Medical Center	Phase 2
Completed	TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors NCT03079440	Asan Medical Center	Phase 2
Unknown	Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients NCT03030508	Shanghai Changzheng Hospital	—
Unknown	Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breas NCT02012634	Xijing Hospital	—